SAN FRANCISCO, Oct. 9, 2019 /PRNewswire-PRWeb/ -- Today, Better Therapeutics, a company developing prescription digital
"Chronic diseases including diabetes and heart disease affect half of all adults in the US and account for nearly 80 cents of every healthcare dollar spent. Digital therapeutics that deliver behavioral interventions focused on lifestyle demonstrate potential benefits over traditional therapies like medications and surgeries that treat the effects of disease while leaving the causes in place. They can increase patient access because they are inherently scalable, continuously delivered, and have demonstrated both clinical and cost-effectiveness in diabetes and hypertension," said Kevin Appelbaum, CEO and study co-author.
The economic analysis estimated cost savings of $145 per patient per month (PPPM) in diabetes, and $97 PPPM in hypertension. These savings are realized by addressing the behaviors and lifestyle factors that are the root causes of disease, reducing the ongoing need for prescription medications. The potential cost savings increases substantially (30-60%) in moderately severe to severe patient populations. The intervention would be cost-effective at total three-year program costs of $6,468 for diabetes and $6,620 for hypertension.
Read the complete study here.
"Our analysis concluded that Better's digital therapeutics for diabetic and hypertensive patients may provide substantial improvements in patient outcomes resulting in lower health resource utilization and costs, mostly resulting from decreased need for medications," said health economist and lead author, Bob Nordyke, PhD.
About Better Therapeutics Better develops prescription software for treating cardiometabolic diseases. By integrating elements of neuroscience, lifestyle medicine, and artificial intelligence, the company has created a new modality for treating a broad range of conditions that share common root causes. The company's digital therapeutics have been validated in peer-reviewed and published clinical trials. Better is commercializing its disease reversal program with health plans, while pursuing regulatory approval of its first prescription digital therapeutic for treating type 2 diabetes. The company is headquartered in San Francisco, CA, and is a member of the Digital Therapeutics Alliance.
SOURCE Better Therapeutics